BioSpace News Archive

I-Mab announced that it has filed its annual report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission on May 1, 2023.

OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call that same day beginning at 8:30 a.m. Eastern time.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary Aptorum Therapeutics Limited (“ATL”) has entered into a non-binding Letter of Intent and Term Sheet (“Term Sheet”) to merge (“Transaction”) its 100% subsidiary, Paths Innovation Limited.

CG Oncology, Inc. announced updated data from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

Tempus today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx . xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.

CorMedix Inc. (Nasdaq: CRMD) today announced that the United States Patent and Trademark Office (USPTO) allowed its patent claims directed to the composition of a catheter lock solution for preventing infection and also preventing reduced blood flow in central venous catheters.

Athersys, Inc. announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.

Neuronetics, Inc. announced the addition of Lisa Metzner-Rosas to the Company’s senior leadership team in the role of Senior Vice President, Chief Marketing Officer, effective May 1, 2023.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, announces that registration is open for its second annual Global Medial-Pivot Symposium in Phoenix, Arizona from October 13-14, 2023.